Navigation Links
Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/12/2008

s offset in part by the loss of revenues from Maxygen's collaboration with Roche to develop a Factor VIIa for acute bleeding conditions. That collaboration ended in the second quarter of 2007.

Expenses for the fourth quarter 2007 were $23.7 million, an increase of $5.4 million compared to the fourth quarter 2006. This increase was primarily due to the restructuring charges related to the Denmark facility closure.

Full Year 2007 Results

Maxygen reported a net loss of $49.3 million, or $1.34 per share, for the year ended December 31, 2007, as compared to a net loss of $16.5 million, or $0.46 per share, for the prior year.

Excluding the impact of SFAS 123(R), Maxygen reported a non-GAAP net loss of approximately $42.8 million, or $1.16 per basic and diluted share, in 2007. In 2006, excluding the impact of SFAS 123(R) and the gain on sale of equity investment, Maxygen reported a non-GAAP net loss of approximately $27.4 million, or $0.76 per basic and diluted share.

Conference Call

Maxygen will host a conference call today to discuss fourth quarter and 2007 financial results at 11:30 a.m. ET (8:30 a.m. PT). Participants in the U.S. can access the call by dialing 866.825.3209 and using the passcode 31366535. International participants can dial 617.213.8061 and use the same passcode. A live webcast of the conference call will be available at http://www.maxygen.com/webcasts.

A telephone replay of the conference call will be available until March 12, 2008. To access the replay, please call 888.286.8010 (U.S.) or 617.801.6888 (international) and use the passcode 60709469. An archived version of the webcast will be available until March 12, 2008 at http://www.maxygen.com/webcasts.

About Maxygen

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. The com
'/>"/>

SOURCE Maxygen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Maxygen to Present at the Roth 20th Annual OC Growth Stock Conference
2. Maxygen to Present at the Stanford Group Company 13th Annual Healthcare Conference
3. Maxygen to Present at the JPMorgan 26th Annual Healthcare Conference
4. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
5. Maxygen Reports Third Quarter 2007 Financial Results
6. Maxygen Announces Upcoming Webcasts at Investor Conferences
7. Maxygen Third Quarter 2007 Financial Results Conference Call Notice
8. Maxygen Announces Hold on MAXY-alpha Development Program
9. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of ... They saw continued independent research led by the team ... a $1 million grant from the Susanne Marcus Collins ... a peer reviewed journal, Amy Grant highlighted Brainwave Optimization® ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Associates has announced the development of the Core Communications Program, ... investors, collaborators, and customers. , ... ... http://www.mainsgate.com [Mains Associates] has announced the availability of ...
... electronic properties, few layer graphene, or FLG, has emerged ... devices that incorporate the quantum effects that emerge at ... Pennsylvania have demonstrated a new method by which FLG ... thermally activated nanoparticles, a technique that results in atomically ...
... (Nasdaq: ONXX ) today announced that it ... Pharmaceuticals Conference on,Thursday, August 7, at 3:05 p.m. ... of the presentation on our website at:, http://www.onyx-pharm.com/wt/page/event_calendar ... on 15 minutes early in order to,register and ...
Cached Biology Technology:Bay-Area Company Gives Science-Based Startups a Voice 2Penn scientists carve functional nanoribbons using super-heated, nano-sized particles of iron 2
(Date:7/9/2014)... announce themselves with pain and fever but often can be ... are sneaky and hard to beat. Now, scientists have built ... tiny DNA pyramids. Published in the journal ACS Applied ... flag bacteria and kill more of them than medicine alone. ... infectious pathogens can lie in wait, undetectable in the human ...
(Date:7/9/2014)... developed by researchers at the NIH,s National ... its collaborators to treat sickle cell disease ... business. The drug candidate, Aes-103, is the ... molecular mechanism of sickle cell disease. Baxter ... required for regulatory approval and commercialization. , ...
(Date:7/9/2014)... cancer patients with high levels of vitamin D in their ... shows. , Patients with the highest levels of vitamin ... with the lowest levels, the findings reveal. , The study ... D in bowel cancer patients after their diagnosis which ... from dietary sources with their long term survival prospects. ...
Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... BioScience includes the following peer-reviewed research articles: ... , Yufeng Wang and Timothy G. Lilburn. , The ... in resource collections that are well characterized with the ... sequence data, using ideas from systems biology. ...
... Institute of Harvard and MIT and Beth Israel Deaconess ... previously unrecognized mammalian genes that do not encode proteins, ... presented in the February 1st advance online issue of ... class of "large intervening non-coding RNAs" or "lincRNAs" plays ...
... Louis, MO, USA, February 1, 2009 A special ... Journal of the American Dietetic Association presents findings ... Study (SNDA-III), conducted by Mathematica Policy Research, Inc., as ... Sponsored by the Food and Nutrition Service of the ...
Cached Biology News:BioScience tip sheet, February 2009 2Scientists uncover new class of non-protein coding genes in mammals with key functions 2Scientists uncover new class of non-protein coding genes in mammals with key functions 3Results of the third school nutrition dietary assessment study published 2Results of the third school nutrition dietary assessment study published 3Results of the third school nutrition dietary assessment study published 4
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
Criterion staining and blotting trays are plastic trays designed for staining one or two Criterion gels or performing western blot detection. The trays have a working capacity of up to 500 ml. Suppli...
... range of next-generation features into a small-footprint ... for flexible laboratory solutions. It puts every ... dilution, dispensing, and integrations into a ... flexible as it is efficient and economical. ...
... FX P is the latest entry in ... greater positional accuracy and increased robustness, it can ... It can be configured with either one or ... the Biomek FX P sets the standard ...
Biology Products: